Home Online Features FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
Hand-out
Press Releases
November 14, 2024

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

By U.S. Food and Drug Administration, PTC Therapeutics, Inc.

SILVER SPRING, Md., Nov. 14, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult

bradford

The Bradford Era

email
Local & Social